tirzepatide approved for obesity New Breakthrough Drug Lilly's Zepbound (aka tirzepatide) Lands

This targeted approach ensures that only the fat cells are affected, leaving other tissues unharmed

Safety Profile and Reported Side Effects The most common side effects are gastrointestinal nausea, vomiting, and diarrhoea alongside a modest increase in resting heart rate

BPC-157 vs Physical Therapy: PT is essential, BPC-157 accelerates it Use both together for best results BPC-157 enables more aggressive PT BPC-157 vs NSAIDs: NSAIDs: Reduce pain, slow healing BPC-157: Reduce pain, accelerate healing BPC-157 protects against NSAID damage BPC-157 vs Corticosteroid injections: Steroids: Mask pain, weaken tissue long-term BPC-157: Heal tissue, strengthen long-term BPC-157 is safer for repeated use BPC-157 vs Surgery: Try BPC-157 first for most injuries May avoid surgery for moderate damage Use post-surgery to accelerate recovery For comparison with other performance enhancers, read peptides vs SARMs

The company also acknowledges on its product page that completing an assessment does not create a clinician-patient relationship with the platform itself